Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat


Tytuł :
Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Autorzy :
Schiewer MJ; Department of Urology, Urology Research Laboratory, Thomas Jefferson University, Sidney Kimmel Cancer Center, 233 South 10th Street BLSB 804, Philadelphia, PA 19107, USA; Department of Cancer Biology, Urology Research Laboratory, Thomas Jefferson University, Sidney Kimmel Cancer Center, 233 South 10th Street BLSB 804, Philadelphia, PA 19107, USA. Electronic address: .
Knudsen KE; Department of Cancer Biology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Urology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Medical Oncology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA; Department of Radiation Oncology, Thomas Jefferson University, 233 South 10th Street BLSB 1050, Philadelphia, PA 19107, USA. Electronic address: https://twitter.com/SKCCDirector.
Pokaż więcej
Źródło :
The Urologic clinics of North America [Urol Clin North Am] 2021 Aug; Vol. 48 (3), pp. 339-347. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*pathology
Receptors, Androgen/*genetics
Androgen Antagonists/therapeutic use ; Biomarkers, Tumor/genetics ; Cell Plasticity ; DNA Repair ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Genetic Testing ; Germ-Line Mutation ; Humans ; Male ; Precision Medicine ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology
Czasopismo naukowe
Tytuł :
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Autorzy :
Fan L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fei X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhu Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pan J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Sha J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chi C; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gong Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Du X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhou L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dong B; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xue W; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Feb; Vol. 205 (2), pp. 461-469. Date of Electronic Publication: 2020 Sep 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sequence Analysis, DNA*
Circulating Tumor DNA/*blood
Circulating Tumor DNA/*genetics
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*genetics
Aged ; Androgen Antagonists/therapeutic use ; Genomics ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Autorzy :
Fersino S; Radiation Oncology Department, Azienda Provinciale per i Servizi Sanitari, Ospedale S.Chiara, Largo Medaglie d'oro, 9, 38122, Trento, Italy. .
Borghesi S; Radiotherapy Unit- Ospedale S. Donato e Santa Maria alla Gruccia, Azienda USL Toscana Sud, Arezzo, Italy.
Jereczek-Fossa BA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Arcangeli S; UOC Radioterapia ASST Monza, Università di Milano, Bicocca, Italy.
Mortellaro G; Department of Radiation Oncology, ARNAS Ospedale Civico, Palermo, Italy.
Magrini SM; Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Alongi F; Advanced Radiation Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar-Verona, Italy.; University of Brescia, Brescia, Italy.
Pokaż więcej
Corporate Authors :
Uro-Oncology study group of Italian association of Radiotherapy and Clinical Oncology (AIRO)
Źródło :
La Radiologia medica [Radiol Med] 2021 Mar; Vol. 126 (3), pp. 460-465. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Journal Article
MeSH Terms :
Attitude of Health Personnel*
Radiation Oncologists*
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Health Care Surveys/*statistics & numerical data
Prostatic Neoplasms/*drug therapy
Androstenes/therapeutic use ; Combined Modality Therapy/methods ; Gonadotropin-Releasing Hormone/agonists ; Humans ; Italy ; Male ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatectomy ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/radiotherapy ; Risk Factors ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł :
Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Autorzy :
Xu MC; Vanderbilt University School of Medicine, Nashville, Tennessee.
Huelster HL; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Hatcher JB; Vanderbilt University School of Medicine, Nashville, Tennessee.
Avulova S; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Stocks BT; Vanderbilt University School of Medicine, Nashville, Tennessee.
Glaser ZA; Vanderbilt University School of Medicine, Nashville, Tennessee.
Moses KA; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Silver HJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Mar; Vol. 205 (3), pp. 800-805. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Obesity/*complications
Prostatic Neoplasms/*pathology
Sarcopenia/*complications
Adipose Tissue/diagnostic imaging ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Muscle, Skeletal/diagnostic imaging ; Neoplasm Metastasis ; Neoplasm Staging ; Obesity/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Sarcopenia/diagnostic imaging ; Survival Rate ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
Treating Prostate Cancer by Antibody-Drug Conjugates.
Autorzy :
Rosellini M; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Santoni M; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Mollica V; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Rizzo A; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Cimadamore A; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Scarpelli M; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Storti N; Direzione Sanitaria Azienda Sanitaria Unica Regionale, 60122 Ancona, Italy.
Battelli N; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Montironi R; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Massari F; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 04; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Immunoconjugates/*therapeutic use
Prostatic Neoplasms/*drug therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Biomarkers, Tumor ; Clinical Trials as Topic ; Disease Management ; Disease Susceptibility ; Humans ; Immunoconjugates/pharmacology ; Male ; Molecular Targeted Therapy ; Prognosis ; Prostatic Neoplasms/etiology ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/etiology ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Standard of Care ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Contemporary management of advanced prostate cancer: an evolving landscape.
Autorzy :
Khanna A; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
O'Connor LP; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Murthy PB; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Bryk DJ; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Fascelli M; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Ericson K; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Yerram NK; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Haywood SC; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Abouassaly R; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Pokaż więcej
Źródło :
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2021 Feb; Vol. 19 (2), pp. 108-118.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Therapies, Investigational*
Adenocarcinoma/*therapy
Prostatic Neoplasms/*therapy
Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/secondary ; Androstenes/therapeutic use ; Benzamides/therapeutic use ; Clinical Trials as Topic ; Combined Modality Therapy ; Diagnostic Imaging/methods ; Disease Management ; Docetaxel/therapeutic use ; Humans ; Male ; Multicenter Studies as Topic ; Nitriles/therapeutic use ; Phenylthiohydantoin/therapeutic use ; Precision Medicine ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/therapy ; Radiotherapy, Adjuvant ; Radium/therapeutic use ; Taxoids/therapeutic use
Czasopismo naukowe
Tytuł :
4,4'-Diisothiocyanatostilbene-2,2'-disulfonate modulates voltage-gated K current and influences cell cycle arrest in androgen sensitive and insensitive human prostate cancer cell lines.
Autorzy :
George K; Department of Biomedical Engineering, Chennai Institute of Technology, Chennai, India.; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Thomas NS; Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, India.
Malathi R; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Pokaż więcej
Źródło :
Toxicology mechanisms and methods [Toxicol Mech Methods] 2020 Jun; Vol. 30 (5), pp. 358-369. Date of Electronic Publication: 2020 Apr 01.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/*pharmacology
Antineoplastic Agents/*pharmacology
Cell Cycle Checkpoints/*drug effects
Potassium Channel Blockers/*pharmacology
Potassium Channels, Voltage-Gated/*antagonists & inhibitors
Receptors, Androgen/*metabolism
Apoptosis/drug effects ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Humans ; Male ; Membrane Potentials/drug effects ; PC-3 Cells ; Patch-Clamp Techniques ; Potassium Channels, Voltage-Gated/metabolism ; Prostate/drug effects ; Prostate/metabolism ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Tetraethylammonium/pharmacology
Czasopismo naukowe
Tytuł :
Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Autorzy :
Zhang Y; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Chen B; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Xu N; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Xu P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Lin W; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Liu C; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Huang P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Jan 12; Vol. 16, pp. 315-327. Date of Electronic Publication: 2021 Jan 12 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Androgens/*pharmacology
Exosomes/*metabolism
Heme Oxygenase-1/*metabolism
Prostatic Neoplasms/*pathology
Up-Regulation/*drug effects
Animals ; Cell Line, Tumor ; Disease Progression ; Exosomes/ultrastructure ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice, Inbred NOD ; Mice, SCID ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Autorzy :
Jakob T; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tesfamariam YM; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Macherey S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematological Malignancies, Cologne, Germany.
Kuhr K; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Adams A; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Monsef I; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Heidenreich A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Skoetz N; Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Dec 03; Vol. 12. Cochrane AN: CD013020. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Bone Neoplasms/*secondary
Denosumab/*therapeutic use
Diphosphonates/*therapeutic use
Prostatic Neoplasms/*pathology
RANK Ligand/*antagonists & inhibitors
Adult ; Alendronate/adverse effects ; Alendronate/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology ; Bone Density Conservation Agents/adverse effects ; Clodronic Acid/adverse effects ; Clodronic Acid/therapeutic use ; Denosumab/adverse effects ; Diphosphonates/adverse effects ; Etidronic Acid/adverse effects ; Etidronic Acid/therapeutic use ; Humans ; Male ; Network Meta-Analysis ; Pamidronate/adverse effects ; Pamidronate/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Risedronic Acid/adverse effects ; Risedronic Acid/therapeutic use ; Zoledronic Acid/adverse effects ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Autorzy :
Janzen BW; Postgraduate Medical Education.
Ong A; Section of Radiation Oncology.
Penner M; Canadian Mennonite University, Winnipeg, MB, Canada.
Koul R; Section of Radiation Oncology.
Dubey A; Section of Radiation Oncology.
Ahmed S; Section of Radiation Oncology.
Bashir B; Section of Radiation Oncology.
Chowdhury A; Section of Radiation Oncology.
Dawe DE; Section of Hematology/Oncology, Department of Internal Medicine.; Section of Urology, Department of Surgery, Max Rady College of Medicine.
Nayak J; Section of Urology, Department of Surgery, Max Rady College of Medicine.
Kim JO; Section of Radiation Oncology.; Research Institute in Hematology and Oncology, CancerCare Manitoba, University of Manitoba.
Pokaż więcej
Źródło :
American journal of clinical oncology [Am J Clin Oncol] 2020 Dec 01; Vol. 43 (12), pp. 865-871.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Prostatic Neoplasms/*drug therapy
Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Aged ; Aged, 80 and over ; Humans ; Kallikreins/blood ; Male ; Manitoba/epidemiology ; Marital Status ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Radiation Oncologists ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł :
EGFR as a stable marker of prostate cancer dissemination to bones.
Autorzy :
Nastały P; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Stoupiec S; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Popęda M; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Smentoch J; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Schlomm T; Department of Urology, Charité University Hospital Berlin, Berlin, Germany.
Morrissey C; Department of Urology, University of Washington, Seattle, WA, USA.
Żaczek AJ; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Beyer B; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tennstedt P; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Graefen M; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eltze E; Institute of Pathology Saarbruecken-Rastpfuhl, Saarbruecken, Germany.
Maiuri P; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Semjonow A; Department of Urology, Prostate Center University Clinic Münster, Münster, Germany.
Pantel K; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Brandt B; University Medical Centre Schleswig-Holstein, Kiel, Germany.
Bednarz-Knoll N; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. .; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2020 Dec; Vol. 123 (12), pp. 1767-1774. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*secondary
Neoplastic Cells, Circulating/*metabolism
Prostatic Neoplasms/*pathology
Biomarkers, Tumor/genetics ; Bone Neoplasms/mortality ; Cell Movement ; Collagen Type I/genetics ; Epithelial-Mesenchymal Transition ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Feasibility Studies ; Flow Cytometry ; Humans ; Immunohistochemistry ; Male ; Neoplastic Cells, Circulating/pathology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Vimentin/metabolism
Czasopismo naukowe
Tytuł :
Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
Autorzy :
Tabrizi S; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: .
Alshalalfa M; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Radiation Oncology, University of California, San Francisco, California.
Mahal BA; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Davicioni E; Decipher Biosciences, San Diego, California.
Liu Y; Decipher Biosciences, San Diego, California.
Mouw KW; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Feng F; Department of Radiation Oncology, University of California, San Francisco, California.
Nguyen PL; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Muralidhar V; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Pokaż więcej
Źródło :
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 Nov 15; Vol. 108 (4), pp. 936-940. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*metabolism
Microtubule-Associated Proteins/*metabolism
Neoplasm Proteins/*metabolism
Neuroendocrine Tumors/*metabolism
Neuropeptides/*metabolism
Prostatic Neoplasms/*metabolism
Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Confidence Intervals ; Humans ; Linear Models ; Male ; Neuroendocrine Tumors/mortality ; Neuroendocrine Tumors/pathology ; Prostate/metabolism ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Statistics, Nonparametric
Czasopismo naukowe
Tytuł :
Preoperative MRI-based estimation of risk for positive resection margin after radical prostatectomy in patients with prostate cancer: development and validation of a simple scoring system.
Autorzy :
Park MY; Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Park KJ; Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. .
Kim MH; Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Kim JK; Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2021 Jul; Vol. 31 (7), pp. 4898-4907. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji :
Journal Article
MeSH Terms :
Margins of Excision*
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/surgery
Humans ; Magnetic Resonance Imaging ; Male ; Neoplasm Grading ; Prostatectomy ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Lu-PSMA for advanced prostate cancer: are we ready to play big?
Autorzy :
Hehakaya C; Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. .
Moors EHM; Innovation Studies, Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, The Netherlands.
Verkooijen HM; Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Grobbee DE; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Verburg FA; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Lam MGEH; Division of Imaging & Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Jul; Vol. 48 (8), pp. 2325-2328.
Typ publikacji :
Editorial
MeSH Terms :
Prostatic Neoplasms*/radiotherapy
Prostatic Neoplasms, Castration-Resistant*/radiotherapy
Dipeptides ; Heterocyclic Compounds, 1-Ring ; Humans ; Lutetium ; Male
Opinia redakcyjna
Tytuł :
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Autorzy :
Wenzel M; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Nocera L; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Collà Ruvolo C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Italy.
Würnschimmel C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Tian Z; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Departments of Urology, Weill Cornell Medical College, New York, New York.; Department of Urology, University of Texas Southwestern, Dallas, Texas.; Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Saad F; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Briganti A; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Graefen M; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Kluth LA; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Mandel P; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Chun FKH; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Jul; Vol. 206 (1), pp. 69-79. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
African Americans/*statistics & numerical data
European Continental Ancestry Group/*statistics & numerical data
Healthcare Disparities/*statistics & numerical data
Hispanic Americans/*statistics & numerical data
Prostatic Neoplasms/*therapy
Aged ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/pathology ; Retrospective Studies ; Risk Assessment
Czasopismo naukowe
Tytuł :
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
Autorzy :
Bruinsma SM; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Nieboer D; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.
Roobol MJ; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Bangma CH; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Verbeek JFM; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Gnanapragasam V; Academic Urology Group, Department of Surgery & Oncology, University of Cambridge, Cambridge, United Kingdom.
Van Hemelrijck M; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.
Frydenberg M; Department of Urology, Cabrini Institute, Cabrini Health, Melbourne, Australia.; Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
Lee LS; Department of Urology, Sengkang General Hospital, Singapore, Singapore.; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Valdagni R; Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Prostate Cancer Program, Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Logothetis C; MD Anderson Cancer Centre, Houston, Texas.
Steyerberg EW; Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Jul; Vol. 206 (1), pp. 62-68. Date of Electronic Publication: 2021 Feb 22.
Typ publikacji :
Journal Article; Validation Study
MeSH Terms :
Patient Selection*
Prostatic Neoplasms*/pathology
Prostatic Neoplasms*/therapy
Watchful Waiting*
Aged ; Biopsy ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Risk Assessment
Czasopismo naukowe
Tytuł :
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds.
Autorzy :
Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Buck SAJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
de Wit R; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jul; Vol. 32 (7), pp. 831-832. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Prostatic Neoplasms*/diagnosis
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms, Castration-Resistant*
Androstenes ; Benzamides ; Humans ; Male ; Nitriles ; Phenylthiohydantoin ; Prognosis ; Taxoids ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Lactoferrin-Bearing Gold Nanocages for Gene Delivery in Prostate Cancer Cells in vitro.
Autorzy :
Almowalad J; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Somani S; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Laskar P; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Meewan J; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Tate RJ; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Mullin M; College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
Dufès C; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Jun 30; Vol. 16, pp. 4391-4407. Date of Electronic Publication: 2021 Jun 30 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Gene Transfer Techniques*
Drug Carriers/*chemistry
Gold/*chemistry
Lactoferrin/*chemistry
Prostatic Neoplasms/*genetics
Prostatic Neoplasms/*pathology
DNA/administration & dosage ; DNA/chemistry ; DNA/genetics ; Genetic Therapy ; Humans ; Male ; Plasmids/genetics ; Polyethylene Glycols/chemistry ; Polyethyleneimine/chemistry ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/therapy ; Transfection
Czasopismo naukowe
Tytuł :
Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages.
Autorzy :
Wang F; Clinical Metabolomics Center, China Pharmaceutical University, School of Traditional Chinese Pharmacy, Nanjing, China.
Fan Y; Clinical Metabolomics Center, China Pharmaceutical University, School of Traditional Chinese Pharmacy, Nanjing, China.
Yin X; Clinical Metabolomics Center, China Pharmaceutical University, School of Traditional Chinese Pharmacy, Nanjing, China.
Qi LW; Clinical Metabolomics Center, China Pharmaceutical University, School of Traditional Chinese Pharmacy, Nanjing, China.
Ma G; Clinical Metabolomics Center, China Pharmaceutical University, School of Traditional Chinese Pharmacy, Nanjing, China.
Yuan Q; Department of Urology, The Fifth People's Hospital of Wuxi, Wuxi, China.
Pokaż więcej
Źródło :
Aging [Aging (Albany NY)] 2021 Jun 29; Vol. 13 (12), pp. 16773-16785. Date of Electronic Publication: 2021 Jun 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Prostatectomy*
Prostatic Neoplasms/*epidemiology
Prostatic Neoplasms/*radiotherapy
Age Factors ; Aged ; Confidence Intervals ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Prostatic Neoplasms/pathology ; SEER Program ; Survival Analysis
Czasopismo naukowe
Tytuł :
Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.
Autorzy :
Sun X; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Wang L; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Li H; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Jin C; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Yu Y; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Hou L; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Liu X; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Yu Y; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Yan R; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Xue F; Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.; Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China.
Pokaż więcej
Źródło :
Aging [Aging (Albany NY)] 2021 Jun 16; Vol. 13 (12), pp. 16024-16042. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Prostatectomy*
Tumor Microenvironment*/genetics
Adenocarcinoma/*pathology
Adenocarcinoma/*surgery
Biomarkers, Tumor/*metabolism
Neoplasm Recurrence, Local/*pathology
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*surgery
Adenocarcinoma/genetics ; Adenocarcinoma/immunology ; Confounding Factors, Epidemiologic ; Databases, Genetic ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Gene Ontology ; Genome, Human ; Humans ; Male ; Middle Aged ; Prognosis ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/immunology ; Receptors, Androgen/metabolism ; Reproducibility of Results ; Stromal Cells/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies